Dong-A ST Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
148,993
317,696
301,020
285,877
192,303
218,268
Total Accounts Receivable
102,258
92,759
129,379
157,503
108,727
91,596
Inventories
93,109
86,663
96,623
105,873
98,550
103,101
Other Current Assets
4,291
2,593
2,610
12,265
13,220
13,521
Total Current Assets
348,650
499,711
529,632
561,517
412,799
426,486
Net Property, Plant & Equipment
445,018
461,091
411,525
366,209
335,775
326,102
Total Investments and Advances
121,457
104,475
99,705
102,846
128,043
183,018
Long-Term Note Receivable
-
-
-
1,675
1,130
1,855
Intangible Assets
12,968
14,470
20,063
15,803
12,998
11,205
Other Assets
3,625
346
1,301
18,567
8,973
7
Total Assets
931,718
1,081,858
1,063,539
1,066,617
899,719
948,673
ST Debt & Current Portion LT Debt
80,768
127,706
144,457
252,763
120,450
Accounts Payable
29,857
28,525
32,223
27,812
30,567
Income Tax Payable
3,771
5,861
10,112
2,165
1,137
Other Current Liabilities
57,233
61,890
51,497
103,406
67,400
Total Current Liabilities
171,629
223,983
238,289
386,146
219,554
Long-Term Debt
274,353
321,019
228,116
39,894
59,892
Provision for Risks & Charges
8,473
13,821
16,064
1,073
9,025
Deferred Taxes
25,829
19,029
15,807
10,410
6,073
Other Liabilities
12,074
13,904
10,177
39,872
23,983
Total Liabilities
492,358
593,521
509,765
477,395
318,526
Common Equity (Total)
438,827
488,073
553,613
589,222
581,193
Total Shareholders' Equity
438,827
488,073
553,613
589,222
581,193
Total Equity
439,361
488,337
553,773
589,222
581,193
Liabilities & Shareholders' Equity
931,718
1,081,858
1,063,539
1,066,617
899,719
Accumulated Minority Interest
534
263
160
-
-

About Dong-A ST Co.

View Profile
Address
64 Cheonhodae-ro
Seoul SL 02587
Korea, Republic Of
Employees -
Website http://www.donga-st.com
Updated 07/08/2019
Dong-A ST Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products includes medicines for gastric mucous membrane protection, antihistanminic agetnts, ischemic improvements, antithrombotic, functional digestion, hyperlipemia cure, growth hormone, antipeptic ulcer cure, cerebral metabolic, high blood pressure, and others. The company was founded on March 4, 2013 and is headquartered in Seoul, South Korea.